BioMarin Pharmaceuticals (BMRN)

• Market cap: $12.5B
• 1 day: 1.02%
• 5 days: -1.26%
• 1 month: 4.96%
• 3 months: -7.12%
• 6 months: -22.49%
• Year to date: -33.03%
• 1 year: -29.14%
• 5 years: -22.53%
• 10 years: -29.25%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Employees: 3,401

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $152M | Put options by funds: $112M

1% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 191

6% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 93

1% less funds holding

Funds holding: 548 [Q2] → 542 (-6) [Q3]

5.1% less ownership

Funds ownership: 98.04% [Q2] → 92.94% (-5.1%) [Q3]

19% less capital invested

Capital invested by funds: $15.3B [Q2] → $12.4B (-$2.89B) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 1% downside
• Avg. target: $89 36% upside
• High target: $109 66% upside

11 analyst ratings

• positive: 7 64%
• neutral: 4 36%
• negative: 0 0%

Cantor Fitzgerald Olivia Brayer 54% 1-year accuracy 13 / 24 met price target	37% upside $90	Overweight Reiterated	12 Dec 2024
Wolfe Research Akash Tewari 23% 1-year accuracy 3 / 13 met price target	45% upside $95	Outperform Initiated	15 Nov 2024
Citigroup David Lebovitz 76% 1-year accuracy 13 / 17 met price target	23% upside $81	Neutral Maintained	30 Oct 2024
Canaccord Genuity Whitney Ijem 21% 1-year accuracy 8 / 39 met price target	28% upside $84	Hold Maintained	30 Oct 2024
JP Morgan Jessica Fye 50% 1-year accuracy 20 / 40 met price target	66% upside $109	Overweight Maintained	30 Oct 2024